Status:
COMPLETED
Observational Study of Fat Loss in HIV Infected Adults Taking Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Conditions:
HIV Infections
Lipodystrophy
Eligibility:
All Genders
18+ years
Brief Summary
Nucleoside reverse transcriptase inhibitors (NRTIs) are a class of anti-HIV (Human Immunodeficiency Virus) drug that can be an important part of an HIV treatment regimen. Because anti-HIV therapy may ...
Detailed Description
NRTIs are a mainstay of HIV treatment regimens, often part of initial treatment regimens for newly diagnosed patients. Recent data suggest that NRTIs are responsible for lipoatrophy, a condition marke...
Eligibility Criteria
Inclusion
- HIV-1 infected
- Treatment-naive
- Plan to initiate first ARV regimen with 2 NRTIs and an NNRTI
- Plan to include zidovudine as part of first ARV regimen
Exclusion
- Current use of steroids or growth hormone
- Coagulopathies or other bleeding disorders
- Pregnancy or breastfeeding
Key Trial Info
Start Date :
April 1 2005
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 1 2010
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT00119405
Start Date
April 1 2005
End Date
November 1 2010
Last Update
March 30 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospitals of Cleveland
Cleveland, Ohio, United States, 44106